

4<sup>th</sup> New Horizons in

# Immunotherapy for Head and Neck Cancer

August 16 – 17, 2019  
The Allison Inn  
Newberg, OR

## COURSE DIRECTORS

### **R. Bryan Bell, MD, DDS, FACS**

Earle A. Chiles Research Institute  
at Robert W. Franz Cancer Center  
Providence Cancer Institute  
Portland, OR

### **Ezra Cohen, MD**

USCD Moores Cancer Center  
University of California San Diego  
San Diego, CA

### **Robert L. Ferris, MD, PhD**

UPMC Hillman Cancer Center  
University of Pittsburgh  
Medical Center  
Pittsburgh, PA

Continuing Medical Education Provider



EARLE A. CHILES  
RESEARCH INSTITUTE



## COURSE OVERVIEW

Cancer immunotherapy has rapidly advanced in recent years. This course is designed to provide a forum for leaders in the field of head and neck cancer to disseminate the science and clinical data underlying the clinical benefits of immunotherapy and to increase awareness of the role of the immune system in head and neck cancer therapy, as a single modality or in combination with conventional therapies (chemotherapy and radiation). Current research and advancements in treating head and neck cancer will be discussed, and attendees will have an opportunity to gain an understanding of available immunotherapy agents and a rationale for ongoing and future clinical trials. This conference will be interactive and geared towards development of further strategies for development of clinical trials, implementing new therapies in the practice setting and looking to the future treatment of head and neck cancer.

## TARGET AUDIENCE

This conference is designed for leaders in head and neck cancer who are interested in advancements in the field of immunotherapy for the treatment of cancer patients including medical oncologists, radiation oncologists, otolaryngologists, oral surgeons, primary care physicians, pediatricians, family practitioners, nurse practitioners, physician assistants, residents, audiologists, speech therapists, and other interested health care professionals.

## PROFESSIONAL PRACTICE GAPS

As cancer immunotherapy is an emerging field of practice, clinicians and scientists may not be aware of ongoing and future clinical trials testing various immunotherapeutic agents in head and neck cancer patients. An awareness of recent data on immunotherapies in head and neck cancer, which populations are suitable for available agents, and understanding novel approaches to stimulating the immune system in these disease processes is lacking. Familiarity with new developments in cancer immunotherapy can expand treatment options and improve outcomes for patients with head and neck cancer.

## ASSESSMENT OF NEED

Leaders in the field head and neck cancer are in need of timely updates and knowledge related to advances in the treatment of head and neck cancer to improve patient outcomes. These leaders have expressed a need for a forum in which to present clinical studies in an effort to develop the evidence for incorporating immune-oncologic agents into the treatment of head and neck cancer.

## METHODOLOGY/FORMAT

In addition to didactic lectures on the past, present and future of head and neck cancer therapy, there will be abundant discussion and debate regarding the therapy and application to the treatment of cancer. Ongoing clinical studies will be presented as well as an exchange of ideas and direction for future development.

## OBJECTIVES

Upon completion of this meeting, the attendee should be able to:

1. Review recent developments in cancer immunotherapy for the treatment of head and neck cancer.
2. Describe what is known about immune checkpoint blockade and design a strategy for testing these agents in head and neck cancer, alone and in combination with other immune modulators.
3. Explain a rationale for the exploration of co-stimulatory agonists in the treatment of head and neck cancer.
4. Discuss evolving vaccine strategies for the treatment of HPV-related and non-HPV related head and neck cancer.
5. Discuss advances in neoantigen directed and adoptive cell therapy in head and neck cancer.
6. Articulate the changes in the head and neck cancer tumor microenvironment and discuss methods to reverse immunosuppression.

## CONTINUING MEDICAL EDUCATION

### Accreditation



Pfiedler Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

### Credit Designation

Pfiedler Education designates this live continuing education activity for a maximum of **14.5 AMA PRA Category 1 Credits™**. Physicians should claim only credit commensurate with the extent of their participation in the activity.

## FACULTY

### **Clint T. Allen, MD, PhD**

Johns Hopkins Otolaryngology Consult  
National Institutes of Health  
Associate Professor  
Otolaryngology – Head and  
Neck Surgery  
Bethesda, MD

### **Jason Baird, PhD**

Earle A. Chiles Research Institute at  
Robert W. Franz Cancer Center  
Providence Cancer Institute  
Portland, OR

### **Joshua Brody, MD**

Mount Sinai Hospital  
New York, NY

### **Tullia Bruno, PhD**

University of Pittsburgh Medical Center  
Pittsburgh, PA

### **Lisa Butterfield, PhD**

Parker Institute for  
Cancer Immunotherapy  
San Francisco, CA

### **Marka Crittenden, MD, PhD**

Earle A. Chiles Research Institute at  
Robert W. Franz Cancer Center  
Providence Cancer Institute  
Portland, OR

### **Nora Disis, MD, PhD**

University of Washington  
Seattle, WA

### **Rebekka Duhon, PhD**

Earle A. Chiles Research Institute at  
Robert W. Franz Cancer Center  
Providence Cancer Institute  
Portland, OR

### **Bernard Fox, PhD**

Earle A. Chiles Research Institute at  
Robert W. Franz Cancer Center  
Providence Cancer Institute  
Portland, OR

### **Michael Goldberg, PhD**

Dana Farber Cancer Center  
Boston, MA

### **Michael Gough, PhD**

Earle A. Chiles Research Institute at  
Robert W. Franz Cancer Center  
Providence Cancer Institute  
Portland, OR

### **Zhen Gu, PhD**

UCLA California Nanosystems Institute  
University of California Los Angeles  
Los Angeles, CA

### **Kevin Harrington, MD**

The Institute of Cancer Research  
The Royal Marsden Hospital  
London, UK

### **Stephan Lang, MD**

University Hospital Essen  
Essen, Germany

### **Rom Leidner, MD**

Earle A. Chiles Research Institute at  
Robert W. Franz Cancer Center  
Providence Cancer Institute  
Portland, OR

### **Luc Morris, MD, MSc**

Memorial Sloan Kettering  
Cancer Center  
New York, NY

### **David Mooney, PhD**

Wyss Institute  
Harvard University  
Boston, MA

### **Sara Pai, MD, PhD**

Massachusetts General Hospital  
Harvard University  
Boston, MA

### **Kelly Paulson, MD, PhD**

University of Washington  
Seattle, WA

### **Tanguy Siewert, MD**

University of Chicago  
Chicago, IL

### **Steve Shoenberger, PhD**

La Jolla Institute for Allergy  
and Immunology  
La Jolla CA

### **Andrew Sikora, MD, PhD**

Baylor College of Medicine  
Houston, TX

### **Michael Spiotto, MD**

University of Chicago  
Chicago, IL

### **John Sunwoo, MD**

Stanford University  
Stanford, CA

### **Ravi Uppaluri, MD, PhD**

Dana Farber Cancer Center  
Harvard University  
Boston, MA

### **Rieneke van de Ven, PhD**

VU University Medical Center  
Amsterdam  
Amsterdam, Netherlands

### **Dario Vignali, PhD**

UPMC Hillman Cancer Center  
University of Pittsburgh Medical Center  
Pittsburgh, PA

### **Jared Weiss, MD**

UNC Lineberger Comprehensive  
Cancer Center  
University of North Carolina  
Chapel Hill, NC

### **Kristina Young, MD**

Earle A. Chiles Research Institute at  
Robert W. Franz Cancer Center  
Providence Cancer Institute  
Portland, OR

### **Simon Young, MD, DDS, PhD**

UT Health Science Center at Houston  
University of Texas  
Houston, TX

All faculty participating in continuing medical education activities provided by Pfiedler Education are expected to disclose to the audience any real or apparent financial relationships related to the content of their presentations. Detailed disclosure will appear in writing and be distributed on-site prior to the course, and will also be made verbally during the faculty presentation at the live event.

## COURSE DIRECTORS

### **R. Bryan Bell, MD, DDS, FACS**

Medical Director  
Oral, Head and Neck Cancer Program and Clinic  
Providence Cancer Center  
Providence Portland Medical Center  
Attending Surgeon  
Trauma Service/Oral and Maxillofacial Surgery Service  
Legacy Emanuel Medical Center  
Affiliate Professor  
Oregon Health and Science University  
The Head and Neck Institute  
Portland, Oregon

### **Ezra Cohen, MD**

Professor of Medicine  
UC San Diego Moores Cancer Center  
San Diego, California

### **Robert L. Ferris, MD, PhD, FACS**

UPMC Endowed Professor  
Vice-Chair for Clinical Operations  
Chief  
Division of Head and Neck Surgery  
Associate Director for Translational Research  
Co-Leader  
Cancer Immunology Program  
University of Pittsburgh Cancer Institute  
Pittsburgh, Pennsylvania

## KEYNOTE SPEAKER

### **Cornelius Melief, MD, PhD**

Leiden University Medical Center  
Leiden, Netherlands

## PRELIMINARY AGENDA

### *Friday, August 16, 2019*

7:30 – 8:00 am      Registration and Breakfast  
  
8:00 – 10:00 am    Session 1: Biomarkers  
  
10:00 – 12:00 pm   Session 2: Vaccines  
  
12:00 – 1:30 pm    Lunch  
  
1:30 – 4:30 pm      Session 3: Neoadjuvant  
                                 Immunotherapy  
  
4:30 – 6:00 pm      Reception

### *Saturday, August 17, 2019*

7:30 – 8:00 am      Breakfast  
  
8:00 – 10:00 am    Session 4: Immunotherapy +  
                                 Radiation  
  
10:00 – 12:00 pm   Session 5: Adoptive Cell Therapy  
  
12:00 – 1:30 pm    Lunch  
  
1:30 – 3:30 pm      Session 6: Beyond Checkpoint  
                                 Inhibitors  
  
3:30 – 5:00 pm      Session 7: Bioengineering +  
                                 Immunotherapy  
  
5:00 – 6:30 pm      Reception

## DECLARATION OF DISCLOSURE FOR PFIEDLER EDUCATION:

In compliance with the ACCME Standards for Commercial Support, Pfiedler Education provides disclosure and resolution of conflict information for individuals who are in control of the content of this CME activity. Please visit our website at: <http://www.pfiedler.com/disclosure>.

## COMMERCIAL SUPPORT

Pfiedler Education gratefully acknowledges the commercial support from companies listed below. All support is managed in accordance with the ACCME Criteria and Standards for Commercial Support.

Grant funds: To be determined

In-kind support: None

## EXHIBITORS

To be determined

## DISCLAIMER

Pfiedler Education does not endorse or promote any commercial product that may be discussed in this activity.

## COURSE VENUE & ACCOMMODATIONS

The Allison Inn  
2525 Allison Lane  
Newberg, Oregon 97132

### *Guest Room Rates*

Room rates start at \$385.00 per night plus applicable sales tax.

Pfiedler Education has reserved a block of rooms **until Tuesday, July 16, 2019**. After that date, reservations will be based upon availability at The Allison Inn's prevailing published rate.

### *Reservation Method*

To make a room reservation, please call the hotel directly at 503-554-2525 or 877-294-2525. Reservations will not be accepted on the hotel website or through third-party channels. Room reservations cancelled with less than a 72-hour notice will be subject to a cancellation fee in the amount of one night room and tax.

## 4<sup>th</sup> New Horizons in Immunotherapy for Head and Neck Cancer

August 16 – 17, 2019 • Newberg, OR

Name \_\_\_\_\_

Healthcare Organization \_\_\_\_\_

MD    DO    DMD    DDS    PhD    Fellow/Resident    Other

Street address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Daytime Phone Number \_\_\_\_\_

Email (Required. Confirmation will be provided to this address) \_\_\_\_\_

DIETARY or PHYSICAL NEEDS – Please indicate \_\_\_\_\_

*Pfiedler Education complies with the American with Disabilities Act (ADA).*

*You may also contact us directly for special requests.*

**REGISTRATION FEE – \$500.00**

**SPOUSE/GUEST FEE – \$150.00**

### REGISTRATION PROCEDURE

Online: [www.pfiedler.com/ce/newhorizons](http://www.pfiedler.com/ce/newhorizons)

Email: [bonnie@pfiedler.com](mailto:bonnie@pfiedler.com)

Mail: Pfiedler Education  
2170 S. Parker Rd., Suite 125  
Denver, CO 80231

### COURSE CANCELLATION POLICY:

*In the event you must cancel your registration, please contact Pfiedler as soon as possible at 720-748-6144. This will allow wait-listed professionals to attend.*

*Please make sure that you receive a course confirmation prior to making travel arrangements. Pfiedler Education reserves the right to cancel this activity if necessary. Registered participants will be notified no later than two weeks prior to the scheduled event date. Pfiedler Education is not responsible for non-refundable tickets purchased to attend this course.*

*Cancellations received less than one week prior to meeting are non-refundable..*

**REGISTER EARLY! ATTENDANCE IS LIMITED!**